Skip to content

Technical research on the efficacy of RTMS in treating obesity in patients with schizophrenia

Technical research on the efficacy of RTMS in treating obesity in patients with schizophrenia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115496
Enrollment
Unknown
Registered
2025-12-26
Start date
2022-09-13
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

True stimulation group:The site for stimulating the left DLPFC is located 125 pixels anterior to the sagittal plane of the maximum abductor pollicis brevis stimulation site. A train of 20 pulses of 5
sham stimulation group:The butterfly-shaped coil was placed on the interhemispheric fissure of the top of the brain, with a relatively low stimulation intensity (10% of the resting motor threshold), w

Sponsors

Suzhou Guangji Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 60 Years

Inclusion criteria

Inclusion criteria: The subjects were hospitalized obese schizophrenia patients aged 15-60 years, with a BMI of >=30kg/m^2, a stable weight (+/-5%) for 6 weeks, meeting the ICD-10 diagnostic criteria for schizophrenia, who were in stable condition (PANSS total score <= 60 points), and were able to complete the program.

Exclusion criteria

Exclusion criteria: 1. History of head injury or epilepsy/seizures; 2. pacemakers, in vivo metal implants, and other contraindications to fMRI or rTMS; 3. Use of weight loss drugs or very low-calorie diet, pregnancy or lactation, eating disorders, or substance dependence within the past year; 4. Unstable cardiovascular disease (myocardial infarction or stroke within the last 1 year, heart failure, acute limb ischemia, severe peripheral arterial occlusive disease); 5. other potential causes of obesity (hypothyroidism, Cushing's syndrome, hypogonadism, insulinoma) documented in the medical history or physical examination; 6. Those who are currently using cochlear implants.

Design outcomes

Primary

MeasureTime frame
Change in BMI in obese patients with schizophrenia;Changes in resting-state brain function in DLPFC brain regions before and after rTMS treatment;

Secondary

MeasureTime frame
Change in body weight at baseline examination;Change in average total daily caloric intake;Change in appetite VAS score;Changes in cognitive function;

Countries

China

Contacts

Public ContactGuangya Zhang

Suzhou Guangji Hospital

zgyhjq@163.com+86 189 6211 5017

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026